Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158745 | 1.00 | DGAT1 (0.42) | DGAT1NPC1PDE10AEGFRIGF1R | |
| SCHEMBL29663834 | 0.90 | DGAT1 (0.43) | DGAT1PDE10A | |
| SCHEMBL20422628 | 0.90 | DGAT1 (0.43) | DGAT1PDE10A | |
| SCHEMBL25239242 | 0.88 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL15753342 | 0.88 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL30456780 | 0.88 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL20437124 | 0.88 | DGAT1 (0.42) | DGAT1F2RL1 | |
| SCHEMBL21678682 | 0.88 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL21632538 | 0.88 | DGAT1 (0.45) | DGAT1NPC1F2RL1 | |
| SCHEMBL21678419 | 0.86 | DGAT1 (0.39) | DGAT1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023110843-A1 | HETEROBICYCLIC DERIVATIVES AS ITK INHIBITORS | ALMIRALL, S.A. (ES) | 2023-06-22 | — | — | WO | disclosed |